Skip to main content
Category

Research

targeted oncology
ResearchTreatments

Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification

*November 2022* The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of…
laurabbook@gmail.com
December 19, 2022
Onc Live
ResearchTreatments

HARMONIC Evaluates Novel Combination in Growing Population of Never Smokers With Advanced Lung Cancer

*November 2022* Never smokers represent a subgroup of patients with advanced lung cancer whose genetic makeup necessitates the need for targeted therapies and clinical trials aimed at improving outcomes. Compared with smokers, defined as those who smoke over 100 cigarettes in their life, never smokers have associated germline mutations for…
laurabbook@gmail.com
December 19, 2022